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A B S T R A C T
Background
The hallmark of severe hemophilia is recurrent bleeding into joints and soft tissues with progressive joint damage, notwithstanding on-
demand treatment. Prophylaxis has long been used but not universally adopted because of medical, psychosocial, and cost controversies.
Objectives
To determine the effectiveness of clotting factor concentrate prophylaxis in the management of people with hemophilia A or B.
Search methods
We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group’s Coagulopathies Trials Register. In addition, we searched
major electronic databases (MEDLINE, EMBASE, CENTRAL), handsearched relevant journals and abstract books and reference lists
of relevant articles.
Last search of Group’s Coagulopathies Trials Register: 07 April 2011.
Selection criteria
Randomised controlled trials and quasi-randomised controlled trials evaluating people with severe hemophilia A or hemophilia B
receiving prophylactic clotting factor concentrates.
Data collection and analysis
Two authors independently reviewed studies for eligibility, assessed risk of bias and extracted data.
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Main results
Six studies (including 142 participants) were eligible for inclusion. Two compared three-times-a-week prophylactic administration with
on-demand treatment in children with hemophilia. Pooled results from these two studies showed a rate ratio of 0.30 (95% confidence
interval; 0.12 to 0.76) for all bleedings and 0.22 (95% confidence interval 0.08 to 0.63) for joint bleedings favouring prophylaxis.
Results on the number of patients with preserved joints after three to seven years of follow-up were not pooled due to significant
heterogeneity. Three of the remaining four studies evaluated hemophilia A; one showed a statistically significant decrease in frequency
of joint bleeds with prophylaxis compared to placebo, with a rate difference of -10.73 (95% confidence interval -16.55 to -4.91) bleeds
per year. Two studies compared two prophylaxis regimens, failing to demonstrate an advantage of one regimen over the other in terms
of bleeding frequency. The fourth study evaluated hemophilia B and showed fewer joint bleeds with weekly (15 IU/kg) versus bi-weekly
(7.5 IU/kg) prophylaxis, rate difference -3.30 (95% confidence interval -5.50 to -1.10) bleeds per year. Non-significant increases in
both inhibitor and infectious complications were observed in patients on prophylaxis, which occurred more often when using long-
term venous access.
Authors’ conclusions
There is strong evidence from randomised controlled trials and observational trials that prophylaxis preserves joint function in children
with hemophilia as compared to on-demand treatment. There is insufficient evidence from randomised controlled trials to confirm
the observational evidence that prophylaxis decreases bleeding and related complications in patients with existing joint damage. Well-
designed randomised controlled trials and prospective observational controlled studies are needed to establish the best prophylactic
regimen and to assess the effectiveness of prophylactic clotting factor concentrates in adult patients.
P L A I N L A N G U A G E S U M M A R Y
Regular clotting factor replacement therapy to prevent joint disease in people with severe hemophilia A or B
Hemophilia A and B are X-linked inherited bleeding disorders, in which the major clinical problem is repeated bleeding into joints. As
this disorder progresses, joints become deformed and movement limited. Current therapy for treating and preventing bleeding includes
plasma-derived or recombinant clotting factor concentrates. This review includes six randomised controlled trials. Two compare the
regular use of clotting factor concentrates to prevent joint bleeds with their use ’on demand’. Four compare different regimens of
regular use in children and adults with hemophilia. It was clearly evident that preventative therapy, as intravenous infusion of factor
concentrate repeated more times a week and started early in childhood was able to reduce joint deterioration as compared to treatment
administered after bleeding occurred. This favourable effect is due to a consistent reduction in total bleeds and hemarthrosis (bleeding
into joints) and leads to a significant improvement in quality of life. Preventative therapy is linked to an increased factor usage and cost
of treatment. We found weaker evidence (due to lack of data) to show preventative therapy reduced joint deterioration when treatment
is started after joint damage has been established. Further studies are needed to establish the best preventative regimen, i.e. for example
starting time, dosage frequency, minimally effective dose.
B A C K G R O U N D
Hemophilia is an X-linked bleeding disorder due to a coagulation
factor deficiency (factor VIII for Hemophilia A and factor IX for
Hemophilia B) and is classified according to clotting factor level:
severe (with a baseline coagulation factor level of less than 1% of
normal); moderate (with clotting factor levels of 1% to 5%); and
mild (with a clotting factor greater than 5%).
Peoplewithmoderate andmild haemophilia bleed rarely, and often
only after trauma or in association with invasive procedures.
The frequency and severity of bleeding is greatest in people with
severe hemophilia A or B, in which recurrent and often sponta-
neous bleeding into joints and soft tissues (since early childhood)
is the hallmark of severity. The consequence of recurrent joint
bleeding is the development of different degrees of haemophilic
arthropathy.
The availability of clotting factor concentrates has radically
changed the treatment of people with hemophilia, with a sig-
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nificant improvement of morbidity, mortality and quality of life
(QoL) (Lusher 1997). Since the introduction of clotting factor
concentrates, the early on-demand treatment for acute bleeding
episodes is now common practice. This has resulted in a decrease
in the number of joint deformities with respect to untreated or
minimally-treated patients (Ahlberg 1965; Hilgartner 1974).
However, observation of the natural history of haemophilic
arthropathy in people on long-term on-demand treatment shows
that this regimen is clearly sub-optimal. Amilestone study in 1994
reported the results of a longitudinal observation of 477 males
under 25 years of age with severe hemophilia A without inhibitors
who were followed up for six years (Aledort 1994). Patients treated
on demand showed a progressive deterioration of their joint func-
tion in some or all of the joints examined. Repeated bleeding in
the joints has been indicated as the mechanism which, through
abnormal proliferation of the synovial tissue, leads to joint disrup-
tion. At the time of this report’s publication, the preventive use of
clotting factor concentrates given at regular intervals had already
been adopted for several decades in Sweden (Nilsson 1976). Then
in 1994, the Medical and Scientific Advisory Council (MASAC),
of the United States of America’s National Hemophilia Founda-
tion reviewed the Swedish experience with prophylaxis and issued
guidelines stating that prophylaxis should be considered the opti-
mal therapy for children with severe hemophilia A and B (NHF
1994).
In the meanwhile, the focus of managing an individual with
hemophilia has changed from treating an acute bleeding episode to
the comprehensive care of the individual, including the adminis-
tration of clotting factor concentrate outside the hospital or treat-
ment centre, as subsequently theorized and better defined (Teitel
2004).
In fact, the efficacy of prophylaxis is expected to be higher if started
early, i.e. before the establishment of any degree of joint deteri-
oration, and continued as much as possible, as only home care
treatment allows.
In this perspective, currently agreed definitions of prophylaxis
are those proposed by the European Paediatric Network for
HaemophiliaManagement (Berntorp 2003; Ljiung 2000). In par-
ticular, prophylaxis was defined as:
• primary A (determined by age) if regular continuous
treatment is started after the first joint bleed and before the age
of two years;
• primary B (determined by first bleed) if regular continuous
treatment is started before the age of two years without previous
joint bleeds;
• secondary A if regular continuous (long-term) treatment is
started after two or more joint bleeds or at an age of over two
years;
• secondary B if intermittent regular (short-term) treatment
is applied, based on frequent bleed events.
Primary prophylaxis (A or B) and secondary A regimens require
at least three doses per week for 42 weeks per year.
Despite the above recommendations, prophylaxis has not been
universally adopted because of medical, psychosocial, and cost
controversies (Blanchette 2004). In fact, the use of clotting fac-
tor concentrates is the single largest predictor of overall cost in
the care of people with hemophilia (Miners 2004; Miners 2009),
and it prevents its extensive application worldwide. Furthermore,
there is no general agreement on the optimal prophylaxis regi-
men, and some schemes differ from that proposed by the Euro-
pean Paediatric Network which has been recently proven to be
feasible (Feldman 2006; Collins 2009). In addition, evidence is
accumulating about the efficacy of secondary prophylaxis started
in adulthood to slow the progression of hemophilic arthropathy
in already damaged joints or to relieve symptoms, or both, and
improve QoL (Fisher 2003; Hay 2007).
In order to help clarify the open issues and provide optimal treat-
ment recommendations for as many people with hemophilia as
possible, we aim to systematically appraise the available evidence
for the effectiveness of prophylactic administration of factor con-
centrates
O B J E C T I V E S
The objective of this review is to evaluate whether the preventive
use of clotting factor concentrates in people with hemophilia A or
B improves short- and long-term outcomes as measured by one or
more of the following:
Short-term
1. number of bleeding episodes per year or bleeding frequency
2. clotting factor concentrate plasma levels
Long-term
1. clinical joint function
2. orthopedic joint score
3. radiologic joint score
4. QoL measurements
M E T H O D S
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Criteria for considering studies for this review
Types of studies
Randomised or quasi-randomised clinical trials. All identified tri-
als, unpublished or published as an article, an abstract or a letter,
without any language limitations, were eligible.
Types of participants
Children and adults with congenital hemophilia A or B, including
all ages and all degrees of severity. People with factor VIII or IX
inhibitors were excluded.
Types of interventions
Trials included were those where intravenous clotting factor con-
centrates were administered as prophylactic treatment in any for-
mulation (fresh frozen plasma, cryoprecipitate, lyophilised plasma
derived clotting factor concentrate, or recombinant clotting factor
concentrate), any concentration, any frequency and any dose were
compared with no treatment, or on-demand treatment, or with
one or more different prophylaxis regimens. The duration of treat-
ment was greater than a single treatment. At least one treatment
had to be a clotting factor concentrate.
Therefore the comparison groups are as follows:
1. prophylaxis versus placebo;
2. prophylaxis versus on-demand treatment;
3. prophylaxis versus alternative prophylaxis.
Types of outcome measures
Primary outcomes
1. Number of bleeding episodes or bleeding frequency
Secondary outcomes
1. Pain scores
2. Radiologic joint score or radiologic measurements or
descriptions of joint damage
3. Orthopedic joint score or clinical joint function
4. QoL
5. Clotting factor concentrate plasma levels
6. Time loss to school or employment
7. Integration into society
8. Scales recording feeling of well-being and global
functioning
9. Cost effectiveness, cost benefit, cost utilization, cost
minimization
10. Any reported adverse effects or toxicity of clotting factor
concentrates will be recorded (e.g. inhibitors, reactions,
transmission of infection)
Search methods for identification of studies
Electronic searches
Relevant trials were identified from the Group’s Coagulopathies
Trials Register using the term: prophylaxis and hemophilia* or
haemophilia*.
The Coagulopathies Trials Register is compiled from electronic
searches of the Cochrane Central Register of Controlled Trials
(Clinical Trials) (updated each new issue of The Cochrane Library)
and quarterly searches of MEDLINE and the prospective hand-
searching of one journal -Haemophilia. Unpublished work is iden-
tified by searching the abstract books of major conferences: the
EuropeanHaematology Association conference; the American So-
ciety of Hematology conference; the British Society for Haema-
tology Annual Scientific Meeting; and the Congress of the World
Federation of Hemophilia. For full details of all searching activ-
ities for the register, please see the relevant section of the Cystic
Fibrosis and Genetic Disorders Group Module.
Date of the most recent search of the Group’s Coagulopathies
Trials Register: 07 April 2011.
We performed additional searches on MEDLINE (from January
1966 to 14 February 2011), and EMBASE (from 1988 to 14
Feburary 2011) (both on the OVID platform) and CENTRAL
(Issue 4, 2010). For the full search strategies, please refer to the
appendices (Appendix 1; Appendix 2).
Searching other resources
The bibliographic references of all retrieved studies and reviews
were assessed for additional reports of clinical trials. For the 2011
update, handsearching of the proceedings of the International So-
ciety for Thrombosis andHaemostasis bi-annualmeeting and pro-
ceedings of the European Association for Haemophilia and Allied
Disorders were performed for the years 2004 to 2010.
Data collection and analysis
Selection of studies
Two authors independently examined the titles and abstracts of
trials generated from the database searches to identify potentially
relevant studies. They retrieved complete manuscripts for all po-
tentially relevant studies. With the full text manuscripts, the au-
thors independently assessed the studies using a standardised form.
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They resolved differences, regarding which studies to include, by
consensus reached after discussion.
Data extraction and management
Using a structured data form the authors extracted the following
information: characteristics of the study; study participants’ demo-
graphics; the study intervention and co-interventions (including
doses of clotting factor concentrate); study outcomes (including
primary and secondary outcomes). Two authors extracted data in-
dependently and compared the results. They resolved differences
by consensus and referral to the original paper.
Authors considered outcome data if recorded as either individual
events or as events grouped by time periods.
Assessment of risk of bias in included studies
The authors used the standard built-in tool in RevMan 5.1 to
measure the risk of bias and to produce summary figures (RevMan
2011).
The authors assessed the risk of bias using the ’Risk of bias’ assess-
ment tool as documented in section 8.5 of the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011). The
following domains were assessed as having either a low, high or
unclear risk of bias:
• sequence generation;
• allocation concealment;
• blinding (of participants, personnel and outcome assessors);
• incomplete outcome data;
• selective outcome reporting;
• other sources of bias.
Results of the risk of bias assessment are displayed in the risk of
bias tables in the ’Characteristics of included studies’ tables.
Measures of treatment effect
We expected rates of events to be the measures reported for the
primary outcome. We expected rate of events or mean and stan-
dard deviations (SD) to be the measures reported for most of the
secondary outcomes. Consequently, and taking also into account
the high number of events expected for the primary outcome, the
authors chose the rate difference as themeasure of treatment effect
for the primary outcome and risk difference or the mean differ-
ence (MD) for the secondary outcomes. The authors accounted
for any deviation from this plan in the text.
Unit of analysis issues
Hemophilia lends itself to cross-over study design, as it is a chronic
incurable genotypically-stable disease, and treatment with clotting
factor concentrate has a rapid onset and short duration as the fac-
tor VIII and IX physiological half-lives are 12 and 24 hours respec-
tively. Thus, we expected at least some of the studies to be cross-
over in design. As a pre-planned analysis we stated that we would
use the generic inverse variance (GIV) method when individual
patient data were available or after obtaining the relevant data.
If such data were available, we would have analysed any parallel
group studies the same way to allow pooling of data. Otherwise,
we used the standard RevMan method for parallel group trials
(RevMan 2011).
Dealing with missing data
We contacted two authors to obtain additional data, but to date,
none have been received (Gringeri 2011; Manco-Johnson 2007).
Assessment of heterogeneity
If we had included a sufficient number of studies in any meta-
analysis, then we would have assessed clinical heterogeneity by
visual and statistical analysis. For future updates, if we include a
sufficient number of studies, we will use the I2 method to assess
for heterogeneity in meta-analysis. If I2 is equal to or greater than
50% we will consider this indicative of heterogeneity. We have
reported both I2 and Cochran Q chi -squared values.
Assessment of reporting biases
We planned to look for publication bias, checking open trial reg-
istries (www.clinicaltrials.gov) and using visual inspection of the
funnel plot graph (if there were 10 or more included studies).
Given the rarity of the disease and its chronic course, we believe
publication bias is unlikely to occur since any similar trials would
have been openly planned and run in the small hemophilia com-
munity. We investigated outcome reporting bias by looking for
differences between trial reports and the original protocols or chal-
lenging any relevant unreported outcome data.
Data synthesis
Due to the low number of available studies, we have conducted the
meta-analyses of the primary data using a random-effects model.
Sensitivity analysis
We undertook a post hoc sensitivity analysis for adverse events
(central venous catheter (CVC) patients) (Analysis 2.6)
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
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Results of the search
In the study search for the first edition of this systematic review,
using the above search strategies, 890 unique references were iden-
tified. The authors assessed the titles and abstracts, from which
119 unique new articles were retrieved, 29 studies were considered
for inclusion and 4 were finally included. One additional study
was identified by contacting the primary author of an identified
congress abstract. The original selection and extraction was per-
formed by KS and AI.
Study selection and data extraction for the 2011 update were per-
formed in duplicate by EMandMM.A total of 569 new references
were retrieved, fromwhich 82 unique references were identified by
title and abstract scanning and 9 unique articles were identified as
being potentially relevant. Three new references (to two studies)
were finally included.Data about the ’JointOutcome Study (JOS)’
were provided by two of these references (Manco-Johnson 2007),
while data about the ESPRIT study were retrieved in one refer-
ence (Gringeri 2011). Additional details about these two studies
were requested from the authors (Gringeri 2011; Manco-Johnson
2007). For the JOS study we requested additional details about
inhibitors (distributions into the two treatment arms and inhibitor
levels); the data were partially provided by dr Manco-Johnson.
Included studies
Six studies, with a total of 142 participants, were identified as
being relevant and included in the data analysis (Aronstam 1976;
Aronstam 1977; Carlsson 1997; Gringeri 2011; Manco-Johnson
2007; Morfini 1976). There was no disagreement between the
two authors with respect to study relevance. The six studies were
heterogeneous as each study used a different intervention. Given
the available data, a meta-analyses could be performed for two
studies (Gringeri 2011; Manco-Johnson 2007).
One study was performed in theUSA (Manco-Johnson 2007) and
five studieswere conducted inEurope.Two studieswere conducted
in Italy (Gringeri 2011; Morfini 1976), one in Sweden (Carlsson
1997) and two in England (Aronstam 1976; Aronstam 1977).
The four participants in the second English study had participated
in the earlier one. There were approximately six months between
the completion of the first study and the commencement of the
second. All studies were published in English.
Two studies were randomised controlled open studies (Gringeri
2011; Manco-Johnson 2007). Four were cross-over in design (
Aronstam 1976; Aronstam 1977; Carlsson 1997; Morfini 1976),
and all six used bleed frequency as the primary outcome measure.
The interventions were not similar between the studies, leading to
heterogeneous results and an inability to perform an overall meta-
analysis. The two more recent studies allowed us to pool data for
some of the outcomes (Gringeri 2011; Manco-Johnson 2007).
Types of Participants
The JOS study included patients on primary prophylaxis (Manco-
Johnson 2007); the ESPRIT study included patients in primary
and secondary prophylaxis (Gringeri 2011); the remaining four
trials reported data about secondary prophylaxis (Aronstam 1976;
Aronstam 1977;.Carlsson 1997; Morfini 1976).
In one study the participants were people with severe hemophilia
B (factor IX less than 1%) (Morfini 1976). In three studies the
participants were people with severe hemophilia A (factor VIII less
than 1%) (Aronstam 1976; Aronstam 1977; Gringeri 2011). One
study included people with clinically severe hemophilia, where one
participant had a pharmacological moderate level of factor VIII
(1.5%), but behaved clinically as a person with severe hemophilia
A (Carlsson 1997). The JOS study included people with severe
and moderate-severe hemophilia A with factor VIII level below
than2%(Manco-Johnson 2007).The age range of participantswas
from 1 year to 45 years. All participants were male, and none had
inhibitors. The studies varied in sample size with 9, 4, 14, 40, 65
and 10 participants respectively (Aronstam 1976; Aronstam 1977;
Carlsson 1997; Gringeri 2011; Manco-Johnson 2007; Morfini
1976).
Types of Interventions
Four studies were cross-over in design (Aronstam 1976; Aronstam
1977; Carlsson 1997; Morfini 1976). The order of the interven-
tion was randomised, and all participants received both the con-
trol and active treatment. Different interventions were used in
the four studies. The treatment arm was either a larger amount
(Aronstam 1976; Aronstam 1977 ) or a more frequent dosing
schedule (Morfini 1976) of clotting factor concentrate than the
control arm, or a modified prophylaxis dose of clotting factor
concentrate based on individual pharmacokinetic data (Carlsson
1997). The control armwas either a non-physiologic effective dose
of clotting factor concentrate (Aronstam 1976), a physiologic ef-
fective clotting factor concentrate dose (Aronstam 1977; Morfini
1976), or a standard prophylaxis schedule of clotting factor con-
centrate (Carlsson 1997). In the Carlsson study, upon enrolment
in the clinical trial, each patient received a single standard dose
of clotting factor concentrate (factor VIII 25 to 40 IU/kg), and
a pharmacokinetic evaluation was calculated by standard “model-
independent” procedures; the individual’s pharmacokinetic data
were used to fit computer-simulated multiple-dose activity curves
of factorVIII for each case, to clinically achieve a factorVIII trough
level above 1% (Carlsson 1997).
One study compared a regimen of clotting factor concentrate to
increase the factor VIII dose to 25% of the normal compared to
1% of the normal (Aronstam 1976). A second study compared
bi-weekly dosing of clotting factor concentrate to raise factor VIII
to 30% of normal, versus 15% of normal (Aronstam 1977). The
study by Morfini compared the same total dose of factor IX clot-
ting factor concentrate per week, administered either weekly (15
IU/kg) or bi-weekly (7.5 IU/kg) (Morfini 1976). The study by
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Carlsson compared standard dose prophylaxis (25 to 40 IU/kg/
dose) given three times per week with the dose and interval based
on individual pharmacokinetic data (Carlsson 1997). In all four
studies, the clotting factor concentrate dosing interval allowed a
physiological washout period of treatment effect before the cross-
over intervention was undertaken.
The two new studies at the 2011 update were open randomised
controlled trials (Gringeri 2011; Manco-Johnson 2007).These
studies compared a prophylaxis treatment group versus an on-de-
mand treatment group. One study compared a prophylaxis group
with a factor VIII infusion of 25 IU/kg of body weight every other
day versus on-demand treatment with 40 IU/kg of body weight
at the time of joint haemorrhage followed by 20 IU at 24 hours
and 72 hours after the first dose (Manco-Johnson 2007). When
hemarthroses occurred in the prophylaxis group, patients were
treated with 40 IU/kg at the time of joint haemorrhage. The sec-
ond trial compared prophylactic treatment with 25 IU/kg of body
weight three-times weekly versus on-demand treatment with 25
IU/kg of body weight until complete healing (Gringeri 2011).
Types of Outcomes
The primary outcome of interest, bleeding events or bleed fre-
quency, was reported in all six studies. All outcomes were stan-
dardized to event rates per year.
Range of motion of affected joints was collected in one study, but
the data were collected at the completion of the study, after the
participants had experienced both interventions in a cross-over
fashion (Morfini 1976). Data about long-term joint deterioration
and adverse events (inhibitors rate, and infection) were reported
in two studies (Gringeri 2011; Manco-Johnson 2007).
A secondary outcome reported in one study was ’morbidity’, and
it was defined as “time spent in the college sick bay or at hospital,
where more than three hours under medical care was noted as
one day” (Aronstam 1976). A further secondary outcome that
was reported in three studies was the quantity of clotting factor
concentrate administered (Carlsson 1997; Gringeri 2011;Manco-
Johnson 2007). Quality of life data were reported in one study
(Gringeri 2011).
Excluded studies
Thirty-one studies were excluded because they were not RCTs.
We classified these as controlled observations and included them
in an additional table because of their potential use in estimating
the baseline risk and variability of treatment effect size in different
populations (Table 1). Twenty-five studies were excluded after the
first search, an additional reference to one of these studies was
identified during a later search (Feldman 2006). Six other studies
were excluded from the analysis at the 2011 update and details
are presented in the additional tables (Collins 2010; Fischer 2005;
Nemes 2007; Schobess 2008; Tagliaferri 2008; Wu 2011) (Table
1).
Risk of bias in included studies
An overall graphical representation of the risk of bias assessment
is provided in the figures (Figure 1; Figure 2). It was noted in
particular, in relation to blinding, the risk of bias was found to be
high in two studies (Carlsson 1997; Morfini 1976). In relation to
’other potential sources of bias’, one trial was assessed as having a
high risk of bias due to a significant number of patients crossing
over the allocated treatment arms (Gringeri 2011).
Figure 1. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
All six studies were described as being randomised, but none re-
ported details about sequence generation. Four studieswere judged
as having suitable concealment (Aronstam 1976; Gringeri 2011;
Manco-Johnson 2007;Morfini 1976). In the remaining two stud-
ies there was no allocation concealment (Aronstam 1977; Carlsson
1997).
Blinding
One study described an appropriate method of double blinding,
where the physicians administering the study treatment were in
a different institution from the physicians evaluating and treat-
ing bleeding episodes (Aronstam 1977). Two studies stated that
the patients were unaware of the treatment administered by the
physician (Aronstam 1976; Aronstam 1977). The ESPRIT study
had a blinded assessment of orthopedic and radiographic scores
(Gringeri 2011). The JOS study had blinded assessment of or-
thopedic and radiographic scores and of laboratory assessments
(Manco-Johnson 2007). The remaining trials were unblinded.
Incomplete outcome data
All six studies discussed withdrawals. Two studies had no with-
drawals (Morfini 1976; Aronstam 1977).One study had twowith-
drawals, these were voluntary discontinuations by two participants
who bled soon after a low dose administration (Aronstam 1976).
The fourth trial had seven withdrawals (four withdrew their con-
sent, three had an unpredictable pharmacokineticmodified dosage
schedule) (Carlsson 1997). The ESPRIT study was analysed by
intention-to-treat, and recorded 8 withdrawals (4 in each arm)
(Gringeri 2011). The JOS study reported 5 (out of 32)withdrawals
in the prophylaxis group and 11 (out of 33) (3 for life-threatening
haemorrhages) in the on-demand group (Manco-Johnson 2007).
This study was analysed by intention-to-treat.
Selective reporting
Selective reporting was assessed only for trials with registered pro-
tocols. The only protocol found was for the JOS trial, registered at
the end of enrolment (September 2005) on www.clinicaltrials.gov
(NCT00207597) (Manco-Johnson 2007). All the outcomes re-
ported in the protocol were analysed in the published paper. The
main outcome was identical in the protocol and the published
paper. For the remaining studies we assessed correspondence be-
tween methods and results sections. It was difficult to judge the
occurrence of non reporting of clinically relevant for the older tri-
als included in the review.
Other potential sources of bias
It was reported in three studies that they were sponsored by phar-
maceutical companies (Carlsson 1997; Gringeri 2011; Manco-
Johnson 2007). One study did not record sponsorship (Morfini
1976). Three studies received financial support from external
sources (Aronstam 1976; Aronstam 1977; Carlsson 1997). A sig-
nificant degree of cross-over between the two treatment arms was
reported for ESPRIT trial (Gringeri 2011). The four studies de-
signed as cross-over did not have a wash out period and did not
take any other method to avoid or account for carry-over effect.
Effects of interventions
Standard prophylaxis regimen compared to a placebo
regimen
One study was included in the comparison (Aronstam 1976). The
characteristics of the included study were:
• Type of prophylaxis: secondary prophylaxis
• Age range: 13 years to 17 years old
• Follow-up duration: at least two school terms
• Number of enrolled patients: 9
Primary outcome
1. Bleeding frequency
The clinical trial found a statistically significant advantage for the
higher dose of factor VIII as compared to a non-physiologic dose
with a rate difference for bleeding frequency of -10.73 (95% CI -
16.55 to -4.91) bleeds per year (Analysis 1.1).
Secondary Outcomes
1. Pain Scores
This outcome was not reported.
2. Radiologic joint score
This outcome was not reported.
3. Orthopedic joint score
This outcome was not reported.
4. QoL
This outcome was not reported.
5. Clotting factor concentrate levels
This outcome was not reported.
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6. Time loss to school or employment
The study assessed morbidity, defined as “time spent in the college
sick bay or at the hospital” (Analysis 1.2). The mean rate differ-
ence was statistically significant (P < 0.05), favouring treatment
of children on the high-dose regimen (factor VIII 0.25 IU/kg),
who spent less time confined to bed, rate difference 0.28 (95%
CI 0.20 to 0.40). In this trial individual participant data were not
provided, and therefore a logarithmic rate difference was calcu-
lated (Deeks 2011).
7. Integration into society
This outcome was not reported.
8. Well-being and global functioning
This outcome was not reported.
9. Cost effectiveness, cost benefit, cost utilization, cost
minimization
This outcome was not reported.
10. Adverse events
The study summarized adverse events or complications at the end
of the study, after participants had received both the treatment
and control interventions. However, no participant developed a
factor VIII inhibitor or became hepatitis B surface antigen positive
during the clinical trial (Aronstam 1976).
Standard prophylaxis regimen compared to on-
demand treatment
Two studies were included in the comparison (Gringeri 2011;
Manco-Johnson 2007). The characteristics of the include studies
were:
Gringeri 2011
• Type of prophylaxis: secondary and primary prophylaxis .
• Age range: less than seven years old
• Follow-up duration: median 82.5 months (range: 2
months to 163 months)
• Number of enrolled patients: 40
Manco-Johnson 2007
• Type of prophylaxis: primary prophylaxis
• Age range: less than 30 months
• Follow-up duration: mean 49 months (range: 48 to 58
months)
• Number of enrolled patients: 65
Primary outcome
1. Bleeding frequency
The comparison showed a significant statistical reduction of total
bleeding in patients treated on prophylaxis versus those treated
on demand. The rate difference was calculated for the JOS study
only (Manco-Johnson 2007), since the SD for the main effect was
not reported for the ESPRIT study (because of skewed data distri-
bution) and not provided by the authors upon request (Gringeri
2011). The rate difference for the JOS study was -14.42 (SD 7.91)
for bleed frequency and -4.16 (SD 2.71) for joint bleeds. To pro-
vide a pooled estimate of the effect on bleeding rate, the rate ratio
was used, rate ratio 0.30 (95% CI 0.12 to 0.76), I2 99% (Chi2
196.78, P < 0.00001) (Analysis 2.1). A similar significant reduc-
tion was found when pooling results for joint bleeding, rate ratio
0.22 (95% CI 0.08 to 0.63), I2 98% (Chi2 63.31, P < 0.00001)
(Analysis 2.2). The pooled estimates should be considered with
caution due to the very high level of heterogeneity, very likely due
to the different characteristics of the population in the two stud-
ies. The absolute bleeding rates in the control groups were for all
bleedings 17.7 +/- 9.2 (events per patient per year, mean and SD)
in the JOS study and 0.48 (events per patient per month, mean)
in the ESPRIT study; for joint bleedings 4.9 +/- 3.6 (events per
patient per year, mean and SD) in the JOS study and 0.24 (events
per patient per month) in the ESPRIT study for joint bleeds.
Secondary Outcomes
1. Pain Scores
This outcome was not reported.
2. Radiologic joint score
We did not pool the data for this outcome due to two additional
causes of variability in the two studies (duration of follow-up and
the intensity of treatment in the control group (enhanced on-de-
mand prophylaxis in the JOS study)). Only patients on primary
prophylaxis in the ESPRIT study showed a statistically signifi-
cant protection from joint damage with prophylaxis when this
was compared to standard on-demand treatment (risk difference
0.70 (95% CI 0.39 to 1.01) while the difference in the JOS study
was borderline significant, risk difference 0.15 (95% CI -0.01 to
0.31) (Analysis 2.3). The effectiveness of secondary prophylaxis
was tested in the ESPRIT study only, resulting in a non-signifi-
cant difference, risk difference for reduction in the progression of
radiologic evidence of joint damage 0.32 (95% CI -0.07 to 0.70)
(Analysis 2.3).
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3. Orthopedic joint score
This outcome was not reported.
4. QoL
Only the ESPRIT trial reported data on QoL (Gringeri 2011).
The Haemo-QoL questionnaire showed that overall QoL was of
22.2 (SD 8.2), in a scale from 0 to 100, where 100 indicates
completely deteriorated QoL. When assessing the impact of treat-
ment, a significant difference was found in children receiving on-
demand treatment versus those receiving prophylaxis in the sub-
scale exploring the dimension “family”, which was more impaired
in the on-demand treatment group, MD 32.73 (95% CI 22.30 to
43.16) (Analysis 2.4).
5. Clotting factor concentrate usage
The studies showed a significant increased consumption of fac-
tor VIII in the patients treated with prophylaxis as compared to
those treated on demand. Monthly factor usage per patient on
the ESPRIT trial was 8852 IU and 3981 IU in the prophylaxis
group and in the on-demand group, respectively (Gringeri 2011)
and in the JOS study they were 5880 IU and 1887 IU per patient
per month in the prophylaxis group and in the on-demand group
respectively, MD 5270 IU/month per patient (95% CI 4230 to
6320), I2 0% (Chi2 0.24, P = 0.62) (Analysis 2.5).
6. Time loss to school or employment.
The outcome was not reported.
7. Integration into society
The outcome was not reported.
8. Well-being and global functioning
The outcome was not reported.
9. Cost effectiveness, cost benefit, cost utilization, cost
minimization
In the ESPRIT study a cost analysis was performed (Gringeri
2011). Cost evaluation was based on the annual FVIII consump-
tion. A societal perspective was adopted (third party payer, i.e. the
Italian National Health Service), and all the health care resources
absorbed by the care of patients were specifically considered. With
an average price per IU of recombinant factor VIII concentrates of
EUR 0.75, the cost for one year of prophylaxis was EUR 79,668
compared to EUR 35,829 for one year on on-demand therapy.
The incremental cost-efficacy ratio per bleeding events avoided
in patients on prophylaxis was EUR 7537. The incremental cost-
efficacy ratio for maintaining all joints unaffected over the whole
treatment period was EUR 201,601.12.
10. Adverse events
Both studies reported the rate of infections per treatment group.
When all the enrolled patients were considered, a non-significant
difference against prophylaxis was observed, risk difference 0.14
(95% CI -0.14 to 0.42), I2 75% (Chi2 4.04, P = 0.04) (Analysis
2.6). Analysis of the inhibitor rate was complicated by suboptimal
reporting of inhibitor incidence in both studies. In the Gringeri
study, the incidence of inhibitors was reported without provid-
ing the distribution in high or low-responding/transient inhibitors
(Gringeri 2011). In the JOS study, the assignment to treatment
group of seven low-responding/transient inhibitors was not pro-
vided (Manco-Johnson 2007). Both authors were contacted to ob-
tain additional data, but to date, none have been received. When
compared using the data as reported in the publications, the in-
hibitor rate was not significantly higher in patients on prophylaxis,
risk difference 0.06 (95% CI -0.03 to 0.15) I2 0% (Chi2 0.06, P
= 0.81) (Analysis 2.6).
Adverse events in central venous catheter (CVC) patients
(sensitivity analysis)
Since both infections and inhibitor development are reported to
be more common in patients with CVC, we also analysed adverse
events in this subgroup of patients. Data allowing the comparison
were available from the JOS study only (Manco-Johnson 2007),
since in the ESPRIT study only patients on prophylaxis had CVC
placed (6 out of 10) (Gringeri 2011), and no infection or inci-
dence of inhibitors were recorded in patients without a central vein
access. A non-significant difference was observed, risk difference -
0.03 (95% CI -0.26 to 0.19) (Analysis 2.6). In a further sensitiv-
ity analysis, we calculated the number of patients with CVC and
events in the two studies (6/10 additional patients in the ESPRIT
prophylaxis group), ending with 12/39 and 6/25 infections dur-
ing prophylaxis or on-demand treatment in CVC patients, respec-
tively, and recalculated an unadjusted risk difference of 0.07 (95%
CI -0.15 to 0.29). Similarly for inhibitor rate we found a non-sig-
nificant excess of inhibitors in CVC patients on prophylaxis versus
those on demand (1 out of 29 versus 1 out of 25, respectively with
a risk difference of -0.01 (95% CI -0.11 to 0.10)) (Analysis 2.6),
unadjusted risk difference 0.06 (95% CI -0.06 to 0.18).
Standard prophylaxis regimen compared to an
alternative prophylaxis regimen
Three studies were included in this comparison but could not be
aggregated as one study compared bi-weekly dosing of clotting
factor concentrate given at a dose to raise factor VIII to 30% of
normal, versus a dose to get 15%of normal factor VIII concentrate
post-infusion level (Aronstam 1977), a second study was on peo-
ple with hemophilia B (Morfini 1976), and the third compared
standard dose prophylaxis (25 to 40 IU/kg/dose) given three times
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per week with a regimen in which the dose and interval were based
on individual pharmacokinetic data (Carlsson 1997) .
The characteristics of the include studies were:
Aronstam 1977
• Type of prophylaxis: secondary prophylaxis
• Age range: 13 years to 17 years old
• Follow-up duration: at least two school term
• Number of enrolled patients: 4
Carlsson 1997
• Kind of prophylaxis: secondary prophylaxis
• Age range: 8 years to 42 years old
• Follow-up duration: one year
• Number of enrolled patients: 21 (14 included in the
analysis)
Morfini 1976
• Kind of prophylaxis: secondary prophylaxis
• Age range: 5 years to 45 years old
• Follow-up duration: one year
• Number of enrolled patients: 10
Primary outcome
1. Bleeding frequency
Two studies did not find a statistical significant effect in the bleed-
ing frequency: rate difference of -5.04 (95% CI -17.02 to 6.94)
bleeds per year when comparing two different dosages (Aronstam
1977) (Analysis 3.1); and rate difference -0.14 (95%CI -1.34 to
1.05) bleeds per year when assessing a PK-based regimen (Carlsson
1997) (Analysis 4.1). The Morfini study showed a significant dif-
ference in favour of the bi-weekly versus the once weekly dosing
group, rate difference of -3.30 (95% CI -5.50 to -1.10) bleeds per
year (Morfini 1976) (Analysis 5.1).
Note: as the dosage and frequency of administration of the clotting
factor concentrate was different in the three studies, it was not
possible to combine the studies.
Secondary Outcomes
1. Pain Scores
No studies reported this outcome.
2. Radiologic joint score
The radiological assessments in people with factor IX deficiency
were made at the completion of the study, not at the completion
of the separate interventions. Therefore, it was not possible to
attribute effectiveness of the treatment intervention in this cross-
over design study (Morfini 1976).
3. Orthopedic joint score
The clinical orthopedic evaluations in people with factor IX de-
ficiency were collected at the completion of the study, not at the
completion of the separate interventions. Therefore, it was not
possible to attribute effectiveness of the treatment intervention in
this cross-over design study (Morfini 1976).
4. Quality of life
This outcome was not reported.
5. Clotting factor concentrate levels
One study reported clotting factor concentrate usage (Carlsson
1997). There was a significant difference in favour of the pharma-
cokinetic-optimised dosing group, mean difference of -3300 IU
per month (95%CI -1420 to -5180) (Analysis 4.2).
6. Time loss to school or employment
This outcome was not reported.
7. Integration into society
This outcome was not reported.
8. Well-being and global functioning
This outcome was not reported.
9. Cost effectiveness, cost benefit, cost utilization, cost
minimization
One study reported savings with a PK-based regimen as compared
to a standard prophylaxis regimen (Carlsson 1997). Savings for
14 patients over 6 months were USD 418,000 or GBP 270 (as
calculated in 1997).
10. Adverse events
Two studies summarized adverse events or complications at the
end of the study, after participants had received both the treat-
ment and control interventions. The development of factor VIII
inhibitors or positivity to hepatitis B surface antigen was collected
at the completion of the study, but no participants developed an
inhibitor or became newly hepatitis B surface antigen positive
(Aronstam 1977; Morfini 1976).
D I S C U S S I O N
This systematic review included six studies with a total of 142
participants with a different degree of arthropathy at baseline and
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variable types of interventions, which allowed only partial aggre-
gation of data for clotting factor concentrate usage for the pre-
vention of bleeding in people with hemophilia. On the whole,
these studies provided evidence that prophylactic administration
of clotting factor concentrates is effective in significantly prevent-
ing or slowing down the progression of hemophilic arthropathy.
As a caveat, performing primary prophylaxis (i.e. started before a
significant number of bleeds has occurred) in small children often
requires clinicians to implant a venous access device. The use of
these devices is complicated by local infection in a significant num-
ber of cases. Similarly, patients on prophylaxis in these studies de-
veloped more inhibitors than those receiving on-demand therapy,
although the difference was not statistically significant and poten-
tially associated with venous access implants or infection rather
than to the prophylactic regimen.
The clinical management of people with hemophilia has changed
over the past three decades, i.e. since the oldest clinical studies
included in this review were undertaken. Hemophilia care is now
provided under a comprehensive health care model and with pro-
phylactic or on-demand treatment for the majority of bleeds given
at home, i.e. outside the treatment centre.
The dates of publication of the earlier studies and the events that
have occurred in the intervening years is worthy of comment.
Three of the included studies were performed as early as the 1970s.
Subsequently, the unfortunate events of the blood-borne infec-
tious disease epidemic precluded the design and implementation
of well-designed clinical trials in the 1980s. Later on, the introduc-
tion of recombinant human clotting factor concentrates removed
any residual risk of infection. However, the ability to undertake
a RCT on the effectiveness of prophylaxis was overshadowed by
more than 20 years experience of primary prophylaxis with clot-
ting factor concentrate compared to historical controls (Nilsson
1992; Petrini 1991; Brackmann 1992; Manco-Johnson 1994; van
den Berg 2002). Although not RCTs, the observational studies
indicated clear benefits in the reduction of bleed frequency and
joint deformity. It has therefore been very difficult for investigators
to decide if there was true equipoise in the choice between pro-
phylactic and on-demand treatment. Essentially, coupled with this
established pattern of practice, there are 30 unique observational
studies reporting data from 1960 people with hemophilia under-
going clotting factor concentrate prophylaxis in comparison with
1312 people with hemophilia treated on-demand. Detailed char-
acteristics of these observational studies are listed in an additional
table (Table 1). These non-RCT observational studies have been
used by healthcare providers to justify the use of clotting factor
concentrate in primary prophylaxis in several countries through-
out the world. Finally, and notwithstanding all the evidence above,
two independent groups in the USA (Manco-Johnson 2007) and
Italy (Gringeri 2011) found it ethically and scientifically sound to
compare the widely-used thrice-a-week prophylaxis regimen with
on-demand treatment. Both groups confirmed the superiority of
administering prophylactic factor concentrates, by showing a re-
duction in the bleeding rate and progression of arthropathy. Both
studies, however, demonstrated that hemophilia patients develop
some degree of joint deterioration even when receiving prophy-
laxis. Furthermore, prophylaxis was found to be associated with a
significant increase in the amount of resources used.
Why were the results of these two more recently performed stud-
ies positive and at variance with the four older studies? Bleeding
episodes within and between people with hemophilia can vary
considerably over a period of months. Furthermore, the patho-
logic process which leads to hemophilic arthropathy requires sev-
eral years to produce clinically evident modifications in the af-
fected joints. Only the two more recent of the six studies observed
patients for 10 years (Gringeri 2011) and 4 years (Manco-Johnson
2007), time-spans that can be considered long enough to establish
a significant difference. Of the remaining four studies included in
the analysis, two observed participants for one year, and two for
two or four “English school” terms. The bleeding frequency pe-
riod studied may have been too short to be clinically meaningful,
and the cross-over design could have been suboptimal in assessing
differences in the setting of chronic disease, where information
about effectiveness and optimal duration of the washout period
are largely unknown. Carryover effect from on-demand treatment
to prophylaxis might have negatively biased the effect of prophy-
laxis, while carryover from prophylaxis to on-demand treatment
may have positively inflated the effectiveness of on-demand treat-
ment. Furthermore, it has been repeatedly shown that prophylaxis
exerts its effect mostly in patients whose joints are still unaffected
joints (i.e. after one or at maximum two clinically relevant bleed-
ing episodes). Most of the participants in the older studies had
already presented with some degree of hemophilic arthropathy
(Aronstam 1976; Aronstam 1977; Carlsson 1997; Morfini 1976),
while the patients in the JOS study (Manco-Johnson 2007) and
some of those in the ESPRIT study (Gringeri 2011) qualified to
be considered as receiving primary prophylaxis. Of note, even the
two more recent studies, though focused on prophylaxis in chil-
dren, presented a high degree of heterogeneity, most likely due to
the difference in either the characteristics of the population in-
cluded or the different treatment scheme used for the on-demand
control group (Gringeri 2011, Manco-Johnson 2007). Thus, the
overall estimates of the meta-analyses should be considered with
caution, and it may even have been inappropriate to pool the re-
sults of the two studies to give a point estimate. In addition to the
estimate of the mean effect size, it is important that the clinical
reader, when estimating the reduction in the bleeding frequency
expected for a given patient, considers the appropriate value in
the range of the confidence intervals, assuming that the baseline
risk and the reduction are likely to be inversely correlated with
the age and joint deterioration of the patient.The heterogeneity
between the studies is most evident when considering the long-
term effect of prophylaxis. In fact, only patients on primary pro-
phylaxis in the ESPRIT study, where the control was standard on-
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demand treatment, showed a statistically significant protection of
the joint function, while the difference in the JOS study, where
enhanced prophylaxis was used as a comparator and the follow-
up was shorter, was borderline significant (Analysis 2.3).
Prophylaxis has already been set as a standard in the western world,
but there is still a lack of knowledge about several aspects of this
treatment, as highlighted by the many outcomes that are consid-
ered relevant by hemophilia clinicians (and thus listed among the
outcomes of interest for this review), but which have not been
addressed or reported on by most of the studies. Furthermore,
new randomised comparisons between different regimens to de-
liver prophylaxis are to be expected in the near future. In fact,
during the course of the recent randomised studies and after their
completion, several new issues about prophylaxis in hemophilia
were raised, such as: optimal regimen (including both dose, fre-
quency, individual tailoring by means of escalating-dose proto-
col or PK modelling); optimal starting point and regimen to pre-
serve joint function and minimize inhibitor development (Kurnik
2010); whether or not to continue beyond childhood and the
role of secondary prophylaxis in adult patients, etc. Similarly, sev-
eral pharmacoeconomic evaluations have been published (Collins
2009; Miners 2009). Some of these studies have had a strong im-
pact on the hemophilia community, and are likely to change the
clinical practice in the western world. In low- and middle-income
countries, studies are ongoing to evaluate the effectiveness of low-
dose prophylaxis regimens.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is evidence fromRCTs and observational studies that the use
of prophylactic clotting factor concentrate is effective in decreasing
the frequency of joint bleeds and in partially preventing or slowing
down the development of arthropathy.
Implications for research
Future randomised clinical trials should address the following as-
pects:
1. comparative efficacy, safety and effectiveness of different
prophylactic regimens (escalating versus fixed-dose,
pharmacokinetic-tailored versus fixed-dose);
2. optimal starting and ending age;
3. standardized clinical and radiological outcome measures of
efficacy;
4. long-term cost-effectiveness.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Aronstam 1976
Methods Cross-over study.
Time unit: school term.
Randomised clinical trial.
Participants Country: England.
Participants: males with hemophilia A.
(factor VIII < 1%).
Age Range: 13 - 17 years.
Number enrolled: 9.
Interventions Factor VIII concentrate.
(Blood Products Laboratory - UK).
Arm A: 0.25 U/kg once weekly.
Arm B: 0.01 U/kg once weekly.
Outcomes Bleeding events or frequency.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The authors did not specify sequence gen-
eration methods but specified that it was
generated by the Wessex Medical Informa-
tion Unit
Allocation concealment (selection bias) Low risk Quote:“...the random allocation of trial
subjects to the different regimens at the be-
ginning of each trial term was made by the
Wessex Medical Information Unit”
Blinding (performance bias and detection
bias)
All outcomes
Low risk Patients were blinded to the assignment
treatment; clinicians and assessors were un-
blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data.
Selective reporting (reporting bias) Low risk The study protocol is not available but the
published reports include all expected out-
comes
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Aronstam 1976 (Continued)
Other bias Unclear risk Cross-over study without washout period
Aronstam 1977
Methods Cross-over study.
Time unit: school term.
Randomized clinical trial.
Participants Country: England.
Participants: males with hemophilia A (factor VIII < 1%).
Age Range: 13 - 17 years.
Number enrolled: 4.
All patients completed the study.
Interventions Cryoprecipitate (prepared by Wessex Regional Transfusion Centre) or Kryobulin (pre-
pared by Serological Products, UK).
Arm A: raise factor VIII to 15% twice weekly.
Arm B: raise factor VIII to 30% twice weekly.
Outcomes Bleeding events or frequency.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The authors reported they used a random
sequence generation but did not give de-
tails about methods of sequence genera-
tion: Quote:“ The boys were allocated to
different treatment schedules at random at
the start of the trial.....”
Allocation concealment (selection bias) Unclear risk The authors did not specify methods of
concealment.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Patients and clinicians were blinded to the
assignment treatment
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data.
Selective reporting (reporting bias) Low risk The study protocol is not available but the
published reports include all expected out-
comes
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Aronstam 1977 (Continued)




Time unit: 6 months.
Randomized clinical trial.
Participants Country: Sweden.
Participants: samples with clinically severe hemophilia A (factor VIII < 2%).
Age range: 8 - 42 years.
Number enrolled: 21.
Number completed: 14.
Interventions Factor VIII concentrate (monoclonal antibody plasma derived, high-purity plasma-de-
rived, or recombinant)
Outcomes Bleeding events or frequency.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Published report specifies that is a random
sequence generation but not defines meth-
ods of sequence generation
Allocation concealment (selection bias) Unclear risk The authors did not specify methods of
concealment.
Blinding (performance bias and detection
bias)
All outcomes
High risk No blinding.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Reason of withdrawal were provided.
Selective reporting (reporting bias) Low risk The study protocol is not available but the
published reports include all expected out-
comes
Other bias Unclear risk Cross-over study without washout period.
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Gringeri 2011
Methods 10 years duration.
Randomised clinical trial.
Participants Country: Italy.
Participants: male with severe hemophilia A (factor VIII level <1%)
Median age: 4 years (age less than 7 years).
Number enrolled: 40.
Interventions Recombinant factor VIII concentrate (Recombinate).
Arm A:25 IU per kilogram of body weight 3 times a week.
Arm B: 25 IU per kilogram of body weight until complete healing
Outcomes Joint deterioration, bleed frequency.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “ centralized allocation system
based on a computer generated randomiza-
tion list.....”
Allocation concealment (selection bias) Low risk Quote: “ patients were centrally ran-
domised to be treated on prophylaxis with.
....”
Blinding (performance bias and detection
bias)
All outcomes
Low risk Patients were unblinded, but the outcome
assessors (for musculoskeletal and radio-
logic evaluation) were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data have been in managed in-
tention-to-treat analysis by last observation
carried forward technique. List of cause
for withdrawal: 9 patients refused random-
ization; 3 patients suffered for more than
2 bleeding episodes in the same joints; 3
patients had not bled in the previous 6
months, 1 child had radiologic signs of
arthropathy, 1 child belonged to an unreli-
able (dysfunctional) family
Selective reporting (reporting bias) Low risk The study protocol is not available but the
published reports include all expected out-
comes
Other bias High risk Significant degree of cross-over between
treatment arms.
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Manco-Johnson 2007
Methods 9 years duration.
Time unit: mean 49 month (48-58 month).
Multicentre, open-label trial randomised clinical trial.
Participants Country: USA.
Participants: male with severe and moderate-severe hemophilia A (factor VIII level <2%)
Age: mean 1.6 years (age less than 30 month in all participants)
Number enrolled: 65.
Interventions Recombinant factor VIII concentrate (Kogenate or Kogenate Bayer)
Arm A: 25 IU of factor VIII per kilogram of body weight every other day to prevent
bleeding. When hemarthroses occurred during prophylaxis, patients were treated with
40 IU per kg at the time of joint haemorrhage
Arm B: 40 IU per kg of body weight at the time of joint haemorrhage and 20 IU at 24
hours and 72 hours after the first dose
Outcomes Primary outcome: preservation of index-joint structure.




Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided.
Allocation concealment (selection bias) Low risk Quote: “randomisation was performed
centrally and stratified by site in permuted
blocks of 2, 4 or 6.”
Blinding (performance bias and detection
bias)
All outcomes
Low risk Quote: “The radiologists who reviewed
joint images, the physiotherapists who per-
formed assays were unaware of the patients’
treatment assignments and status with re-
spect to a history of bleeding”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data have been managed in in-
tention-to-treat analysis by last observa-
tion carried forward technique. Patients re-
moved in by protocol analysis: 5/32 (list
of causes for withdrawal: 2 patients devel-
oped high titre inhibitors; 1 patient had
joint damage; 2 patients dropped out) in
the prophylaxis group and 11/33 (list of
causes for withdrawal: 3 for life threatening
haemorrhage; 6 patients had joint damage;
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Manco-Johnson 2007 (Continued)
1 patient dropped out; 1 was lost to follow
up) in the on-demand group
Selective reporting (reporting bias) Low risk The study protocol is published at the end
of enrolment but the published reports in-
clude all expected outcomes and analysed
data following protocol publication




Time unit: 3-month cycles (A-B-A-B versus B-A-B-A).
Randomized clinical trial.
Participants Country: Italy.
Participants: males with hemophilia B (factor IX < 1%).
Age range: 5 - 45 years.
Number enrolled: 10.
Interventions Factor IX concentrate (Bebulin).
Arm A: 7.5 U/kg twice weekly.
Arm B: 15 U/kg weekly.
Outcomes Bleeding events or frequency, joint deterioration.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided.
Allocation concealment (selection bias) Low risk Quote:“ allocation to treatment protocols
wasmade on the basis of randomenvelopes.
....”
Blinding (performance bias and detection
bias)
All outcomes
High risk No blinding.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No missing data.
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Morfini 1976 (Continued)
Selective reporting (reporting bias) Low risk The study protocol is not available but the
published reports include all expected out-
comes
Other bias Unclear risk Cross-over study without washout period.
IU: international units
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Aledort 1994 Prospective observational study.
Astermark 1999 Retrospective observational study.
Brackmann 1992 Retrospective observational study.
Chuansumrit 1995 Retrospective observational study.
Collins 2010 Prospective observational cross-over study.
Courter 2001 Prospective observational study.
Dzinaj 1996 Prospective observational study.
Feldman 2006 Prospective observational single-arm dose-escalation study.
Fischer 2005 Retrospective observational study.
Kavakli 1997 Prospective observational study.
Kreuz 1998 Prospective observational study.
Liesner 1996 Retrospective observational study.
Lofqvist 1997 Retrospective observational study.
Manco-Johnson 1994 Prospective observational study.
Nemes 2007 Prospective observational single arm study.
Nilsson 1970 Retrospective observational study with historical control.
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(Continued)
Nilsson 1976 Prospective observational study with historical control.
Nilsson 1992 Retrospective observational study.
Petrini 1991 Retrospective observational study.
Petrini 2001 Retrospective observational study.
Pettersson 1981 Retrospective observational study with historical control.
Ramsay 1973 Prospective observational study.
Royal 2002 Retrospective observational study with parallel groups.
Schimpf 1977 Prospective observational cross-over study.
Schobess 2008 Prospective observational study.
Smith 1996 Retrospective observational switch study.
Szucs 1996 Prospective observational study.
Tagliaferri 2008 Retrospective observational switch study.
Tusell 2002 Retrospective observational study.
Van den Berg 2001 Retrospective observational single-arm study.
Wu 2011 Prospective observation with historical control.
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D A T A A N D A N A L Y S E S
Comparison 1. Standard prophylaxis versus placebo (factor VIII concentrate (post-infusion level)




participants Statistical method Effect size
1 Bleed frequency 1 Rate difference (Fixed, 95% CI) Totals not selected
2 Morbidity (length of stay) 1 Rate difference (Fixed, 95% CI) Totals not selected
Comparison 2. Standard prophylaxis versus on-demand treatment (factor VIII concentrate)




participants Statistical method Effect size
1 Bleed frequency 2 Rate Ratio (Random, 95% CI) 0.30 [0.12, 0.76]
2 Joint bleeding 2 Rate Ratio (Random, 95% CI) 0.22 [0.08, 0.63]
3 Joint function protection 2 Risk Difference (M-H, Fixed, 95% CI) Totals not selected
3.1 Primary prophylaxis 2 Risk Difference (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 Secondary prophylaxis 1 Risk Difference (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Quality of Life 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
5 Factor concentrate usage [x1000
IU]
2 105 Mean Difference (IV, Fixed, 95% CI) 5.27 [4.23, 6.32]
6 Adverse events 2 Risk Difference (M-H, Random, 95% CI) Subtotals only
6.1 Infections (All patients) 2 105 Risk Difference (M-H, Random, 95% CI) 0.14 [-0.14, 0.42]
6.2 Inhibitors (All patients) 2 105 Risk Difference (M-H, Random, 95% CI) 0.06 [-0.03, 0.15]
6.3 Infections (Patients with
CVC)
1 54 Risk Difference (M-H, Random, 95% CI) -0.03 [-0.26, 0.19]
6.4 Inhibitors (Patients with
CVC)
1 54 Risk Difference (M-H, Random, 95% CI) -0.01 [-0.11, 0.10]
Comparison 3. Standard prophylaxis versus alternative prophylaxis (factor VIII concentrate (post-infusion level)




participants Statistical method Effect size
1 Bleed frequency 1 Rate difference (Fixed, 95% CI) Totals not selected
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Comparison 4. Standard prophylaxis versus alternative prophylaxis (factor VIII concentrate)




participants Statistical method Effect size
1 Bleed frequency 1 Rate difference (Fixed, 95% CI) Totals not selected
2 Clotting factor concentrate
usage [x1000]
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
Comparison 5. Standard prophylaxis versus alternative prophylaxis (factor IX concentrate)




participants Statistical method Effect size
1 Bleed frequency 1 Rate difference (Fixed, 95% CI) Totals not selected
Analysis 1.1. Comparison 1 Standard prophylaxis versus placebo (factor VIII concentrate (post-infusion
level), Outcome 1 Bleed frequency.
Review: Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B
Comparison: 1 Standard prophylaxis versus placebo (factor VIII concentrate (post-infusion level)
Outcome: 1 Bleed frequency





N N IV,Fixed,95% CI IV,Fixed,95% CI
Aronstam 1976 9 9 -10.73 (2.97) -10.73 [ -16.55, -4.91 ]
-50 -25 0 25 50
Favours wkly 0.25IU/mL Favours wkly 0.01IU/mL
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Analysis 1.2. Comparison 1 Standard prophylaxis versus placebo (factor VIII concentrate (post-infusion
level), Outcome 2 Morbidity (length of stay).
Review: Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B
Comparison: 1 Standard prophylaxis versus placebo (factor VIII concentrate (post-infusion level)
Outcome: 2 Morbidity (length of stay)





N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Aronstam 1976 9 9 -1.26 (0.1703) 0.28 [ 0.20, 0.40 ]
0.1 0.2 0.5 1 2 5 10
Favours wkly 0.25IU/mL Favours wkly 0.01IU/mL
Analysis 2.1. Comparison 2 Standard prophylaxis versus on-demand treatment (factor VIII concentrate),
Outcome 1 Bleed frequency.
Review: Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B
Comparison: 2 Standard prophylaxis versus on-demand treatment (factor VIII concentrate)
Outcome: 1 Bleed frequency
Study or subgroup log [Rate Ratio] Rate Ratio Weight Rate Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
Gringeri 2011 -0.7309 (0.0436) 50.0 % 0.48 [ 0.44, 0.52 ]
Manco-Johnson 2007 -1.6882 (0.0525) 50.0 % 0.18 [ 0.17, 0.20 ]
Total (95% CI) 100.0 % 0.30 [ 0.12, 0.76 ]
Heterogeneity: Tau2 = 0.46; Chi2 = 196.78, df = 1 (P<0.00001); I2 =99%
Test for overall effect: Z = 2.53 (P = 0.012)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Favours prophylaxis Favours on demand
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Analysis 2.2. Comparison 2 Standard prophylaxis versus on-demand treatment (factor VIII concentrate),
Outcome 2 Joint bleeding.
Review: Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B
Comparison: 2 Standard prophylaxis versus on-demand treatment (factor VIII concentrate)
Outcome: 2 Joint bleeding
Study or subgroup log [Rate Ratio] Rate Ratio Weight Rate Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
Gringeri 2011 -0.9746 (0.0678) 50.4 % 0.38 [ 0.33, 0.43 ]
Manco-Johnson 2007 -2.0492 (0.1168) 49.6 % 0.13 [ 0.10, 0.16 ]
Total (95% CI) 100.0 % 0.22 [ 0.08, 0.63 ]
Heterogeneity: Tau2 = 0.57; Chi2 = 63.31, df = 1 (P<0.00001); I2 =98%
Test for overall effect: Z = 2.81 (P = 0.0050)
Test for subgroup differences: Not applicable
0.02 0.1 1 10 50
Favours prophylaxis Favours on demand
Analysis 2.3. Comparison 2 Standard prophylaxis versus on-demand treatment (factor VIII concentrate),
Outcome 3 Joint function protection.
Review: Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B
Comparison: 2 Standard prophylaxis versus on-demand treatment (factor VIII concentrate)
Outcome: 3 Joint function protection





n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Primary prophylaxis
Gringeri 2011 8/8 3/10 0.70 [ 0.39, 1.01 ]
Manco-Johnson 2007 27/28 22/27 0.15 [ -0.01, 0.31 ]
2 Secondary prophylaxis
Gringeri 2011 7/13 2/9 0.32 [ -0.07, 0.70 ]
-1 -0.5 0 0.5 1
Favours on demand Favours prophylaxis
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Analysis 2.4. Comparison 2 Standard prophylaxis versus on-demand treatment (factor VIII concentrate),
Outcome 4 Quality of Life.
Review: Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B
Comparison: 2 Standard prophylaxis versus on-demand treatment (factor VIII concentrate)
Outcome: 4 Quality of Life





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Gringeri 2011 21 44 (22.6) 19 11.27 (8.7) 32.73 [ 22.30, 43.16 ]
-20 -10 0 10 20
Favours on demand Favours prophylaxis
30Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.5. Comparison 2 Standard prophylaxis versus on-demand treatment (factor VIII concentrate),
Outcome 5 Factor concentrate usage [x1000 IU].
Review: Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B
Comparison: 2 Standard prophylaxis versus on-demand treatment (factor VIII concentrate)
Outcome: 5 Factor concentrate usage [x1000 IU]





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Gringeri 2011 21 8.852 (3.774) 19 3.98 (2.301) 29.8 % 4.87 [ 2.95, 6.79 ]
Manco-Johnson 2007 32 8.018 (3.419) 33 2.57 (1.1488) 70.2 % 5.44 [ 4.20, 6.69 ]
Total (95% CI) 53 52 100.0 % 5.27 [ 4.23, 6.32 ]
Heterogeneity: Chi2 = 0.24, df = 1 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 9.88 (P < 0.00001)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours on demand Favours prophylaxis
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Analysis 2.6. Comparison 2 Standard prophylaxis versus on-demand treatment (factor VIII concentrate),
Outcome 6 Adverse events.
Review: Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B
Comparison: 2 Standard prophylaxis versus on-demand treatment (factor VIII concentrate)
Outcome: 6 Adverse events












1 Infections (All patients)
Gringeri 2011 6/21 0/19 49.1 % 0.29 [ 0.08, 0.49 ]
Manco-Johnson 2007 6/32 6/33 50.9 % 0.01 [ -0.18, 0.19 ]
Subtotal (95% CI) 53 52 100.0 % 0.14 [ -0.14, 0.42 ]
Total events: 12 (Prophylaxis), 6 (On demand)
Heterogeneity: Tau2 = 0.03; Chi2 = 4.04, df = 1 (P = 0.04); I2 =75%
Test for overall effect: Z = 1.01 (P = 0.31)
2 Inhibitors (All patients)
Gringeri 2011 3/21 2/19 19.1 % 0.04 [ -0.17, 0.24 ]
Manco-Johnson 2007 2/32 0/33 80.9 % 0.06 [ -0.04, 0.16 ]
Subtotal (95% CI) 53 52 100.0 % 0.06 [ -0.03, 0.15 ]
Total events: 5 (Prophylaxis), 2 (On demand)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.06, df = 1 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 1.27 (P = 0.20)
3 Infections (Patients with CVC)
Manco-Johnson 2007 6/29 6/25 100.0 % -0.03 [ -0.26, 0.19 ]
Subtotal (95% CI) 29 25 100.0 % -0.03 [ -0.26, 0.19 ]
Total events: 6 (Prophylaxis), 6 (On demand)
Heterogeneity: not applicable
Test for overall effect: Z = 0.29 (P = 0.77)
4 Inhibitors (Patients with CVC)
Manco-Johnson 2007 1/29 1/25 100.0 % -0.01 [ -0.11, 0.10 ]
Subtotal (95% CI) 29 25 100.0 % -0.01 [ -0.11, 0.10 ]
Total events: 1 (Prophylaxis), 1 (On demand)
Heterogeneity: not applicable
Test for overall effect: Z = 0.11 (P = 0.92)
-0.2 -0.1 0 0.1 0.2
Favours prophylaxis Favours on demand
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Analysis 3.1. Comparison 3 Standard prophylaxis versus alternative prophylaxis (factor VIII concentrate
(post-infusion level), Outcome 1 Bleed frequency.
Review: Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B
Comparison: 3 Standard prophylaxis versus alternative prophylaxis (factor VIII concentrate (post-infusion level)
Outcome: 1 Bleed frequency





N N IV,Fixed,95% CI IV,Fixed,95% CI
Aronstam 1977 4 4 -5.04 (6.11) -5.04 [ -17.02, 6.94 ]
-50 -25 0 25 50
Favours 2x/wk 0.30IU/mL Favours 2x/wk 0.15IU/mL
Analysis 4.1. Comparison 4 Standard prophylaxis versus alternative prophylaxis (factor VIII concentrate),
Outcome 1 Bleed frequency.
Review: Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B
Comparison: 4 Standard prophylaxis versus alternative prophylaxis (factor VIII concentrate)
Outcome: 1 Bleed frequency





N N IV,Fixed,95% CI IV,Fixed,95% CI
Carlsson 1997 14 14 -0.1429 (0.61) -0.14 [ -1.34, 1.05 ]
-4 -2 0 2 4
Favours pharmacokinetic Favours standard
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Analysis 4.2. Comparison 4 Standard prophylaxis versus alternative prophylaxis (factor VIII concentrate),
Outcome 2 Clotting factor concentrate usage [x1000].
Review: Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B
Comparison: 4 Standard prophylaxis versus alternative prophylaxis (factor VIII concentrate)
Outcome: 2 Clotting factor concentrate usage [x1000]





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Carlsson 1997 14 10.3 (2.5) 14 7 (2.58) 3.30 [ 1.42, 5.18 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours PK adjusted Favours fixed dose
Analysis 5.1. Comparison 5 Standard prophylaxis versus alternative prophylaxis (factor IX concentrate),
Outcome 1 Bleed frequency.
Review: Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B
Comparison: 5 Standard prophylaxis versus alternative prophylaxis (factor IX concentrate)
Outcome: 1 Bleed frequency
Study or subgroup
Bi-weekly





N N IV,Fixed,95% CI IV,Fixed,95% CI
Morfini 1976 10 10 -3.3 (1.12) -3.30 [ -5.50, -1.10 ]
-10 -5 0 5 10
Favours bi-weekly Favours weekly
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A D D I T I O N A L T A B L E S
Table 1. Additional non-randomised observational clinical studies
Study ID Methods Participants Interventions Outcomes Notes
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week. Hemophilia
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Table 1. Additional non-randomised observational clinical studies (Continued)
laxis versus late on-
set of prophylaxis in
moderate or severe
hemophilia A). En-
rolled: Cases = 10.
Controls = 7
IU/kg body weight
three times per week













with 30 IU/kg twice
a week if patients
met excalation crite-
ria
Step 3 25 IU/kg
on alternative days if
patients met excala-
tion criteria
Bleeding episodes. excalation criteria:
- target joint devel-
opment
- four ormore bleed-
ing episodes
in a consecutive 3-
month period
- more than 5 joint
bleeding in any pe-
riod of time















































try: UK. Cases: se-
vere hemophilia A
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Table 1. Additional non-randomised observational clinical studies (Continued)
or B. Enrolled:
hemophilia A = 29.
Hemophilia B = 5
40 IU/kg body
weight. Hemophilia
A three times per
week. Hemophilia







try: USA. Cases: se-
vere hemophilia A
and B. Enrolled:
hemophilia A = 13;
hemophilia B = 1
Clotting factor con-
centrate. Dose: fac-
tor VIII 20 IU/kg
body weight. factor
IX 40 IU/kg body
weight. Frequency:
Factor VIII three
times per week (n =
6), and every other
day (n = 7). Factor






























hemophilia A = 52.








B 25-40 IU/kg body
weight twice weekly
Orthope-
dic joint score. Ra-
diologic joint score.






















ter 14 weeks +/- 7
days
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Table 1. Additional non-randomised observational clinical studies (Continued)
































A three times per
week. Hemophilia
B twice per week
Joint bleeds.
Hemarthrosis.















Ramsay 1973 Prospective observa-
tional study.
Coun-
try: UK. Cases: se-
vere hemophilia A
or B. Enrolled:
































A: 1 x 36 U/kg
body weight and
week. Treatment B:
2 x 18 U/kg body
Bleeding episodes.
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Table 1. Additional non-randomised observational clinical studies (Continued)
weight and week.
Treatment C: 3 x 12
U/kg body weight
and week
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Table 1. Additional non-randomised observational clinical studies (Continued)
hemophilia A = 70.
hemophilia B = 5















QoL: quality of life
A P P E N D I C E S
Appendix 1. Search strategies for current version of the review
Database Strategy




#3 (#1 or #2)
MEDLINE (Ovid)
2003 -14th Feb 2011
1 (inherit$ or heredit$ or congenital or severe).mp. (778243)
2 (blood adj5 disorder).mp. (1569)
3 (hemophili$ or haemophili$).mp. (19425)
4 bleed$.mp. (107960)
5 exp blood coagulation disorders/ (72445)
6 exp coagulation protein disorders/ (25400)
7 coagulation factor deficien$.mp. (180)
8 christmas disease$.mp. (215)
9 or/2-8 (174132)
10 1 and 9 (25842)
11 (factor adj3 concentrat$).mp. (7116)
12 plasma.mp. (594094)
13 cryoprecipitat$.mp. (1977)
14 lyophilized plasma.mp. (76)
15 (recombinant adj3 factor$).mp. (6770)
16 or/11-15 (605334)
17 prevent$.mp. (730741)
18 exp primary prevention/ (95951)
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21 (“factor 8” or “Factor 8” or “f viii” or “f VIII” or “F VIII” or
fviii or fVIII or FVIII or f-viii or f-VIII or F-VIII or “factor viii”
or “factor VIII” or “Factor VIII” or “factor 9” or “Factor 9” or “f
ix” or “f IX” or “F IX” or fix or fIX or FIX or f-ix or f-IX or F-IX
or “factor ix” or “factor IX” or “Factor IX”).mp. (27545)
22 and/10,16,20-21 (279)
23 22 (279)
24 limit 23 to yr=“2003 -Current” (145)
EMBASE (Ovid)
2003 - 14th Feb 2011
1 (hemophili$ or haemophili$).mp. (24152)
2 blood disease/ (4208)
3 blood disorder$.mp. (711)
4 blood clotting disorder/ (19027)
5 “blood coagulation disorder”.mp. (65)
6 “coagulation protein disorder”.mp. (0)
7 exp blood clotting factor deficiency/ (33506)
8 coagulation factor deficien$.mp. (255)
9 exp congenital blood clotting disorder/ (27042)
10 christmas disease$.mp. (194)
11 bleed$.mp. (232718)
12 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 (275630)
13 (inherit$ or heredit$ or congenital or severe).mp. (1157640)
14 12 and 13 (39178)
15 exp blood clotting factor concentrate/ (531)
16 coagulation factor deficien$.mp. (255)
17 fresh frozen plasma.mp. (7327)
18 exp plasma/ (51835)
19 plasma.mp. (696927)
20 cryoprecipitat$.mp. (3260)
21 lyophilized plasma.mp. (97)
22 exp recombinant blood clotting factor 8/ (1707)
23 exp recombinant blood clotting factor 9/ (445)
24 recombinant factor$.mp. (2207)
25 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24
(701280)
26 exp prevention/ (731271)
27 exp primary prevention/ (19405)
28 prevent$.mp. (1008998)
29 exp prophylaxis/ (535291)
30 prophyla$.mp. (156872)
31 26 or 27 or 28 or 29 or 30 (1524847)
32 (“factor 8” or “Factor 8” or “f viii” or “f VIII” or “F VIII” or
fviii or fVIII or FVIII or f-viii or f-VIII or F-VIII or “factor viii”
or “factor VIII” or “Factor VIII” or “factor 9” or “Factor 9” or “f
ix” or “f IX” or “F IX” or fix or fIX or FIX or f-ix or f-IX or F-IX
or “factor ix” or “factor IX” or “Factor IX”).mp. (35580)
33 exp blood clotting factor 8/ (15240)
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(Continued)
34 exp blood clotting factor 9/ (5758)
35 32 or 33 or 34 (35580)
36 14 and 25 and 31 and 35 (473)
37 limit 36 to yr=“2003 -Current” (329)








#3 (therap* or intervention* or treat*)
#4 (#1 or #2 or #3)
#51 hemophilia
#62 haemophilia
#73 (#51 or #62)
#8 (#4 and #7)
MEDLINE (Ovid)
Jan 1966-May 2003
1. (inherit$ or heredit$ or congenital).mp.
2. (blood adj5 disorder).mp.
3. (hemophili$ or haemophili$).mp.
4. bleed$.mp.
5. exp blood coagulation disorders/
6. exp coagulation protein disorders/
7. coagulation factor deficien$.mp.
8. christmas disease$.mp.
9. or/2-8
10. 1 and 9




15. (recombinant adj3 factor$).mp.
16. or/11-15
17. prevent$.mp.
18. exp primary prevention/
19. prophyla$.mp.
20. or/17-19
21. (“factor 8” or “f viii” or fviii or “factor viii” or “factor 9” or “f
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(Continued)
5. blood clotting disorder/
6. “blood coagulation disorder”.mp.
7. “coagulation protein disorder”.mp.
8. exp blood clotting factor deficiency/
9. coagulation factor deficien$.mp.




14. (inherit$ or heredit$ or congenital).mp.
15. 13 and 14
16. exp blood clotting factor concentrate/
17. coagulation factor deficien$.mp.





23. exp recombinant blood clotting factor 8/









33. (“factor 8” or “f viii” or fviii or “factor viii” or “factor 9” or “f
ix” or fix or “factor ix”).mp.
34. exp blood clotting factor 8/
35. exp blood clotting factor 9/
36. or/33-35
37. and/15,26,32,36
WH A T ’ S N E W
Last assessed as up-to-date: 9 July 2011.
Date Event Description
10 July 2011 New search has been performed Two new trials have been incorporated into the review
(Gringeri 2011; Manco-Johnson 2007).
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(Continued)
10 July 2011 New citation required and conclusions have changed The conclusions of the review have changed from there being
insufficient evidence assessing the use of prophylactic clotting
factor concentrates, to there being evidence that the use of
these concentrates is effective in decreasing the frequency of
joint bleeds and in partially preventing or slowing down the
development of arthropathy
The number of participants included in the review has in-
creased from 37 to 142, with two new studies added
Alfonso Iorio (previously a co-author) is now lead author on
this review and Kent Stobart (previously lead-author) is now
a co-author. JohnWu has stepped down from the review and
Emanuela Marchesini, Maura Marcucci and Anthony Chan
are new co-authors
H I S T O R Y
Protocol first published: Issue 1, 2002
Review first published: Issue 2, 2005
Date Event Description
7 October 2009 Amended Please note:
We are aware that the update of this review is overdue. The original review
team has stepped down and a new review team is in place and working on the
update. The updated version of this review will be published in 2010
31 October 2008 Amended Converted to new review format.
1 February 2006 New search has been performed The text of the Reviewers’ Conclusions in the abstract has been altered to
make clear that there is a lack of evidence from randomised controlled trials
for the use of prophylaxis.
No new references were found in the latest search for this review
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C O N T R I B U T I O N S O F A U T H O R S
Kent Stobart: protocol development; study selection; data extraction; data entry; development of final review.
Alfonso Iorio: study selection; data extraction; development of final review.
John K. Wu (previous author): protocol development.
New roles in the update
Alfonso Iorio: updated manuscript drafting; development of final review.
Emanuela Marchesini: study selection; data extraction; updated manuscript drafting; development of final review.
Maura Marcucci: study selection; data extraction.
Anthony Chan: development of final review.
Kent Stobart: development of final review.
D E C L A R A T I O N S O F I N T E R E S T
None known.
S O U R C E S O F S U P P O R T
Internal sources
• Alberta Research Centre for Child Health Evidence, Canada.
This support was received for the firs edition of this systematic review
External sources
• Association of Hemophilia Clinic Directors of Canada, Canada.
This support was received for the firs edition of this systematic review
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
In the 2011 update we undertook a post hoc sensitivity analyse for adverse events.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Blood Coagulation Factors [∗therapeutic use]; Factor VIII [∗therapeutic use]; Hemarthrosis [∗prevention & control]; Hemophilia A
[∗complications]; Hemophilia B [∗complications]; Randomized Controlled Trials as Topic
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MeSH check words
Humans
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